Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

61.46
-0.9400-1.51%
Post-market: 61.680.2214+0.36%19:59 EDT
Volume:10.77M
Turnover:663.45M
Market Cap:125.12B
PE:13.53
High:62.61
Open:62.20
Low:61.25
Close:62.40
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.76
T/O Rate:0.53%
Dividend:2.51
Dividend Rate:4.08%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.61
PE(LYR):17.76

Loading ...

Bristol-Myers Squibb Company - Sotyktu Well-Tolerated Through Week 104 with no New Safety Signals

THOMSON REUTERS
·
Sep 17

Bristol-Myers Squibb Price Target Raised to $82.00/Share from $75.00 by Piper Sandler

Dow Jones
·
Sep 17

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 16

Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler

TIPRANKS
·
Sep 16

Bristol-Myers Squibb Keeps Quarterly Dividend at $0.63 a Share, Payable Nov. 2 to Shareholders of Record on Oct. 2

MT Newswires Live
·
Sep 16

Bristol Myers Squibb Announces Dividend

THOMSON REUTERS
·
Sep 16

Piper Sandler Adjusts PT on Bristol-Myers Squibb to $82 From $75, Keeps Overweight Rating

MT Newswires Live
·
Sep 16

Bristol Myers Sues Amgen over Proposed Opdivo Biosimilar

Reuters
·
Sep 16

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 15

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Snowflake, Applied Materials, Dell, Zoom, Bristol-Myers Insider Shock

TIPRANKS
·
Sep 12

Top Bristol-Myers Squibb Executive Makes Major Move With Insider Stock Sale

TIPRANKS
·
Sep 11

RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 11

Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi Disposes of 6,249 Common Shares Worth $403,700.93

Reuters
·
Sep 11

Champions Oncology Q1 Revenue Rises on Research Services Business

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod

TIPRANKS
·
Sep 11

Bristol-Myers Squibb’s Long-Term Psoriasis Study Brings Fresh Data for BMY Investors

TIPRANKS
·
Sep 11